Denosumab: an investigational drug for the management of postmenopausal osteoporosis

Denosumab: an investigational drug for the management of postmenopausal osteoporosis

E Michael LewieckiNew Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, USAAbstract: Denosumab (AMG 162) is an investigational fully human monoclonal antibody with a high affinity and specificity for receptor activator of nuclear factor-κB ligand (RAN...

Description complète

Enregistré dans:
Détails bibliographiques
Auteur principal: E Michael Lewiecki
Format: article
Langue:EN
Publié: Dove Medical Press 2008
Sujets:
Medicine (General)
R5-920
Accès en ligne:https://doaj.org/article/8bc7daaabf8d46a99e2ef8cf5c1cd09a
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
id oai:doaj.org-article:8bc7daaabf8d46a99e2ef8cf5c1cd09a
record_format dspace
spelling oai:doaj.org-article:8bc7daaabf8d46a99e2ef8cf5c1cd09a2021-12-02T03:36:11ZDenosumab: an investigational drug for the management of postmenopausal osteoporosis1177-54751177-5491https://doaj.org/article/8bc7daaabf8d46a99e2ef8cf5c1cd09a2008-08-01T00:00:00Zhttp://www.dovepress.com/denosumab-an-investigational-drug-for-the-management-of-postmenopausal-a1932https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491E Michael LewieckiNew Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, USAAbstract: Denosumab (AMG 162) is an investigational fully human monoclonal antibody with a high affinity and specificity for receptor activator of nuclear factor-κB ligand (RANKL), a cytokine member of the tumor necrosis factor family. RANKL, the principal mediator of osteoclastic bone resorption, plays a major role in the pathogenesis of postmenopausal osteoporosis and other skeletal disorders associated with bone loss. Denosumab inhibits the action of RANKL, thereby reducing the differentiation, activity, and survival of osteoclasts, and lowering the rate of bone resorption. Clinical trials have shown that denosumab increases bone mineral density (BMD) and reduces bone turnover in postmenopausal women with low BMD. Studies to evaluate the fracture risk benefit and long-term safety of denosumab in women with postmenopausal osteoporosis (PMO) are ongoing. Denosumab is a potential treatment for PMO and other skeletal disorders.Keywords: osteoporosis, treatment, denosumab, AMG 162, RANKL, OPG E Michael LewieckiDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 4, Pp 645-653 (2008)
institution DOAJ
collection DOAJ
language EN
topic Medicine (General)
R5-920
spellingShingle Medicine (General)
R5-920
E Michael Lewiecki
Denosumab: an investigational drug for the management of postmenopausal osteoporosis
description E Michael LewieckiNew Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, USAAbstract: Denosumab (AMG 162) is an investigational fully human monoclonal antibody with a high affinity and specificity for receptor activator of nuclear factor-κB ligand (RANKL), a cytokine member of the tumor necrosis factor family. RANKL, the principal mediator of osteoclastic bone resorption, plays a major role in the pathogenesis of postmenopausal osteoporosis and other skeletal disorders associated with bone loss. Denosumab inhibits the action of RANKL, thereby reducing the differentiation, activity, and survival of osteoclasts, and lowering the rate of bone resorption. Clinical trials have shown that denosumab increases bone mineral density (BMD) and reduces bone turnover in postmenopausal women with low BMD. Studies to evaluate the fracture risk benefit and long-term safety of denosumab in women with postmenopausal osteoporosis (PMO) are ongoing. Denosumab is a potential treatment for PMO and other skeletal disorders.Keywords: osteoporosis, treatment, denosumab, AMG 162, RANKL, OPG
format article
author E Michael Lewiecki
author_facet E Michael Lewiecki
author_sort E Michael Lewiecki
title Denosumab: an investigational drug for the management of postmenopausal osteoporosis
title_short Denosumab: an investigational drug for the management of postmenopausal osteoporosis
title_full Denosumab: an investigational drug for the management of postmenopausal osteoporosis
title_fullStr Denosumab: an investigational drug for the management of postmenopausal osteoporosis
title_full_unstemmed Denosumab: an investigational drug for the management of postmenopausal osteoporosis
title_sort denosumab: an investigational drug for the management of postmenopausal osteoporosis
publisher Dove Medical Press
publishDate 2008
url https://doaj.org/article/8bc7daaabf8d46a99e2ef8cf5c1cd09a
work_keys_str_mv AT emichaellewiecki denosumabaninvestigationaldrugforthemanagementofpostmenopausalosteoporosis
_version_ 1718401681270505472

Documents similaires